Blood Pressure, Renal Hemodynamics, and Inflammation

血压、肾脏血流动力学和炎症

基本信息

  • 批准号:
    7624984
  • 负责人:
  • 金额:
    $ 7.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-06-01 至 2012-03-31
  • 项目状态:
    已结题

项目摘要

The incidence of hypertension and vascular dysfunction is high in women with systemic lupus erythematosus (SLE). Inflammatory cytokines are increased during SLE and growing evidence suggests that cytokines can promote hypertension. One possible mechanism by which chronic inflammation may cause SLE hypertension is through impairment of renal function mediated by increased oxidative stress and vascular dysfunction. This may be exacerbated by a reduced expression of PPARgamma in the kidney. PPARgamma is a nuclear transcription factor that has anti-inflammatory and antioxidant affects. Our preliminary data indicates that renal PPARgamma expression is reduced in a mouse model of SLE (NZBWF1); however, its role in SLE hypertension is not clear. The central hypothesis of the currently funded RO1 is that during SLE, inflammatory cytokines TNFalpha and IL-6, and reduced expression of PPARgamma promote oxidative stress leading to endothelial dysfunction. This leads to increased renal vascular resistance and hypertension. This hypothesis is being tested in the following specific aims. 1) To test whether increased RVR and an impaired renal pressure natriuresis relationship contributes to SLE hypertension. 2) To test whether TNFalpha and IL-6 are mediators of impaired renal hemodynamics, tubular function, and hypertension during SLE. 3) To test whether oxidative stress contributes to impaired renal hemodynamics and hypertension during SLE. 4) To test whether reduced renal PPARgamma is an important underlying mechanism contributing to SLE hypertension. Recent data from our laboratory also shows that this model of SLE has visceral obesity and increased circulating levels of the cytokine leptin. Evidence suggests that leptin is important for increased blood pressure during obesity through sympathetic nerve activation, and that individuals with SLE have increased circulating levels of leptin. Therefore, in a new aim, we propose to test the hypothesis that elevated leptin during SLE increases sympathetic nerve activity as another contributing mechanism to SLE hypertension. This career development award will provide additional time at a critical point in my career development that will allow me to expand my research program into this new and exciting area.
女性系统性狼疮患者高血压和血管功能障碍的发生率较高

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL RYAN其他文献

MICHAEL RYAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL RYAN', 18)}}的其他基金

Innate Immune Mediated Changes in Renal Function to Cause Hypertension in Females with Autoimmune Disease
先天免疫介导的肾功能变化导致患有自身免疫性疾病的女性高血压
  • 批准号:
    10714533
  • 财政年份:
    2023
  • 资助金额:
    $ 7.79万
  • 项目类别:
Renal mechanisms of hypertension in autoimmune disease
自身免疫性疾病中高血压的肾脏机制
  • 批准号:
    9339569
  • 财政年份:
    2015
  • 资助金额:
    $ 7.79万
  • 项目类别:
Renal mechanisms of hypertension in autoimmune disease
自身免疫性疾病中高血压的肾脏机制
  • 批准号:
    10436800
  • 财政年份:
    2015
  • 资助金额:
    $ 7.79万
  • 项目类别:
Renal mechanisms of hypertension in autoimmune disease
自身免疫性疾病中高血压的肾脏机制
  • 批准号:
    9113934
  • 财政年份:
    2015
  • 资助金额:
    $ 7.79万
  • 项目类别:
Mississippi Diversity in Hypertension and Cardiorenal Researchers Program
密西西比州高血压和心肾研究人员多样性计划
  • 批准号:
    8616569
  • 财政年份:
    2014
  • 资助金额:
    $ 7.79万
  • 项目类别:
Mississippi Diversity in Hypertension and Cardiorenal Researchers Program
密西西比州高血压和心肾研究人员多样性计划
  • 批准号:
    8829330
  • 财政年份:
    2014
  • 资助金额:
    $ 7.79万
  • 项目类别:
Blood Pressure, Renal Hemodynamics, and Inflammation
血压、肾脏血流动力学和炎症
  • 批准号:
    7834567
  • 财政年份:
    2009
  • 资助金额:
    $ 7.79万
  • 项目类别:
Blood Pressure, Renal Hemodynamics, and Inflammation
血压、肾脏血流动力学和炎症
  • 批准号:
    7449931
  • 财政年份:
    2008
  • 资助金额:
    $ 7.79万
  • 项目类别:
Blood Pressure, Renal Hemodynamics, and Inflammation
血压、肾脏血流动力学和炎症
  • 批准号:
    8051642
  • 财政年份:
    2008
  • 资助金额:
    $ 7.79万
  • 项目类别:
Blood Pressure, Renal Hemodynamics, and Inflammation
血压、肾脏血流动力学和炎症
  • 批准号:
    7800439
  • 财政年份:
    2008
  • 资助金额:
    $ 7.79万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 7.79万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 7.79万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 7.79万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 7.79万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 7.79万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 7.79万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 7.79万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 7.79万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 7.79万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 7.79万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了